Jul 10, 2023
OncoBeta® GmbH, a medical device company specialised in innovative epidermal radioisotope therapies, has confirmed the phase IV international multi-centre study designed to further evaluate the Complete Response Rate of patients with non-melanoma skin...
May 17, 2023
Non-invasive therapy for non-melanoma skin cancer is now available at select GenesisCare treatment sites
Mar 01, 2023
Australia - While Australians are good at looking for changes in their own skin, over 50% of Australians have not had their skin checked by a health professional within the last two years, and three in 10 have never had a skin check, according to new...
Dec 21, 2022
OncoBeta® GmbH today announced the Steve Biko Academic Hospital in Pretoria, South Africa, is participating in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of non-melanoma skin cancer).
Nov 22, 2022
The latest campaign urging Australians to get their skin checked
Sep 29, 2022
OncoBeta® GmbH, a medical device company specialising in innovative epidermal radioisotope therapies, today announces the Sydney Brachytherapy Group is the first private clinic in NSW performing Rhenium-SCT® for patients with non-melanoma skin cancers...
Sep 27, 2022
OncoBeta® GmbH today announced King's College Hospital in London, United Kingdom, is the latest medical facility to participate in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of...
Jul 27, 2022
OncoBeta® GmbH has announced University Clinic of Rostock is participating in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT) – for the treatment of non-melanoma skin cancer [NMSC]) treating its first...
Jun 15, 2022
OncoBeta® GmbH today announced Perth's Hollywood Private Hospital in Australia is the latest medical facility to participate in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of...
Apr 12, 2022
OncoBeta® GmbH has announced its first Sydney-based patients were treated with Rhenium-SCT® as part of the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of non-melanoma skin cancer [NMSC]).